The Medical Letter on Drugs and Therapeutics
Fidaxomicin (Dificid) for Clostridium Difficile Infection
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved fidaxomicin (Dificid – Optimer), a new oral macrolide antibiotic, for treatment of Clostridium difficile-associated diarrhea in patients ≥18 years old. The incidence and severity of C. difficile infection (CDI) have increased in recent years with the emergence of an epidemic hypervirulent strain (NAP1/B1/027), possibly related to widespread use of fluoroquinolones.

STANDARD TREATMENT — Initial Episode – Oral metronidazole and oral vancomycin have been the drugs of choice for treatment of CDI for many years.1 Oral metronidazole is recommended for initial treatment of mild to moderate CDI. Oral vancomycin is the drug of choice for severe CDI. CDI is generally considered severe when patients have an increase in serum creatinine to ≥1.5 times baseline or a white blood cell count of ≥15,000 cells/mm3. Other risk factors ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Fidaxomicin (Dificid) for Clostridium Difficile Infection
Article code: 1373a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian